# Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

> **NCT02884037** · — · COMPLETED · sponsor: **Mansoura University** · enrollment: 50 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Rifaximin group 1

## Key facts

- **NCT ID:** NCT02884037
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-05
- **Final completion:** 2016-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02884037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02884037, "Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02884037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*